Company Filing History:
5 out of 40 
1 out of 832,812 Years Active: 2007-2017
Title: **Matthias Lechmann: Innovator in Immunology**
Introduction
Matthias Lechmann is a notable inventor based in Bamberg, Germany, renowned for his contributions to the field of immunology. With a robust portfolio of six patents, his work is pivotal in understanding and treating diseases related to cellular immune responses.
Latest Patents
Among his significant contributions, Matthias Lechmann's latest patents focus on the use of soluble forms of CD83 and nucleic acids encoding them for the treatment or prevention of diseases. The first patent details methods utilizing soluble forms of CD83 for addressing dysfunctions in cellular immune responses involving dendritic cells, T cells, and/or B cells. This invention includes the development of antibodies against specific soluble CD83 proteins and associated assay methods and kits.
The second patent expands upon this by detailing the use of soluble CD83 proteins and the nucleic acids encoding them for targeting diseases linked to T cell dysfunction. This involves an extensive description of pharmaceutical compositions containing these proteins, nucleic acids, and vectors, intending to provide critical insights into potential therapeutic applications.
Career Highlights
Matthias has worked with several organizations that are at the forefront of research and development in immunotherapy, notably Argos Therapeutics, Inc. He has made substantial advancements in the field and continues to influence how diseases caused by immune system dysfunction are approached.
Collaborations
Throughout his career, Matthias Lechmann has collaborated with esteemed colleagues such as Alexander Steinkasserer and Elisabeth Zinser. These collaborative efforts have contributed significantly to his innovative research and have fostered a spirit of inquiry and advancement in their shared field.
Conclusion
Matthias Lechmann exemplifies the innovative spirit of inventors dedicated to enhancing human health through scientific discovery. His work on CD83 and its applications signifies a promising direction in the treatment of immune-related diseases, marking him as a key figure in the landscape of modern immunology research.